Secarna Pharmaceuticals Overview
- Year Founded
-
2015

- Status
-
Private
- Employees
-
15

- Latest Deal Type
-
Angel
Secarna Pharmaceuticals General Information
Description
Operator of a profit-making antisense drug discovery and development company intended to meet the medical needs in immuno-oncology and immunology. The company offers third-generation antisense oligonucleotide which encompasses all aspects of drug discovery and pre-clinical development, bringing novel, highly specific, safe, and efficacious app store optimization therapies to patients in the fields of oncology, central nervous system diseases, and beyond, enabling partner companies to discover novel antisense-based therapies for challenging or currently undruggable targets.
Contact Information
Website
www.secarna.comCorporate Office
- Am Klopferspitz 19
- Martinsried
- 82152 Planegg
- Germany
Corporate Office
- Am Klopferspitz 19
- Martinsried
- 82152 Planegg
- Germany
Secarna Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Angel (individual) | 11-Nov-2019 | Completed | Startup |
Secarna Pharmaceuticals Patents
Secarna Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023250231-A1 | Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (lrrk2) and its use for preventing and/or treating human diseases | Pending | 08-Apr-2022 | ||
CA-3241898-A1 | Nlrp3 oligonucleotide for use in preventing and/or treating an inflammatory disease | Pending | 23-Dec-2021 | ||
EP-4453213-A1 | Nlrp3 oligonucleotide for use in preventing and/or treating an inflammatory disease | Pending | 23-Dec-2021 | ||
AU-2021414304-A1 | Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression | Pending | 31-Dec-2020 | ||
CA-3203395-A1 | Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression | Pending | 31-Dec-2020 | A61K31/7125 |
Secarna Pharmaceuticals Signals
Secarna Pharmaceuticals FAQs
-
When was Secarna Pharmaceuticals founded?
Secarna Pharmaceuticals was founded in 2015.
-
Where is Secarna Pharmaceuticals headquartered?
Secarna Pharmaceuticals is headquartered in Planegg, Germany.
-
What is the size of Secarna Pharmaceuticals?
Secarna Pharmaceuticals has 15 total employees.
-
What industry is Secarna Pharmaceuticals in?
Secarna Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Secarna Pharmaceuticals a private or public company?
Secarna Pharmaceuticals is a Private company.
-
What is Secarna Pharmaceuticals’s current revenue?
The current revenue for Secarna Pharmaceuticals is
.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »